Get the Stockscreener App
1.99
2.94%
-0.05
Phio Pharmaceuticals Corp stock is traded at $1.99, with a volume of 115.20K.
It is down -2.94% in the last 24 hours and up +3.13% over the past month.
Phio Pharmaceuticals Corp is a clinical-stage biotechnology company whose proprietary INTASYL self-delivering RNAi technology platform is designed to make immune cells more effective in killing tumor cells. The Company is developing therapeutics that are designed to leverage INTASYL to precisely target specific proteins that reduce the body's ability to fight cancer, without the need for specialized formulations or drug delivery systems.
See More
Previous Close:
$2.04
Open:
$2.03
24h Volume:
115.20K
Relative Volume:
0.04
Market Cap:
$9.55M
Revenue:
-
Net Income/Loss:
$-11.66M
P/E Ratio:
-0.244
EPS:
-8.156
Net Cash Flow:
$-11.09M
1W Performance:
+13.14%
1M Performance:
+3.13%
6M Performance:
-27.21%
1Y Performance:
-70.75%
1-Day Range:
$1.95
$2.03
1-Week Range:
$1.71
$2.08
52-Week Range:
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
Name
Phio Pharmaceuticals Corp
Sector
Industry
Phone
(508) 767-3861
Address
11 APEX DRIVE, SUITE 300A, MARLBOROUGH, MA
Compare PHIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.99 | 8.83M | 0 | -11.66M | -11.09M | -8.156 |
|
ONC
Beone Medicines Ltd Adr
|
246.87 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.41 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.32 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
80.91 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
492.90 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-05-20 | Initiated | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp Stock (PHIO) Latest News
Best Value Stocks to Buy for May 28th - Zacks Investment Research
New Strong Buy Stocks for May 28th - TradingView
New Strong Buy Stocks For May 28th - Barchart.com
Phio Pharmaceuticals (NASDAQ:PHIO) Trading 2.8% Higher – Time to Buy? - Defense World
Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference - Newsfile
Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update - Newsfile
Phio Cancer Treatment Shows Breakthrough Results: 44% Complete Response Rate in Latest Clinical Trial Data - Stock Titan
Metric Deep Dive: Understanding Phio Pharmaceuticals Corp (PHIO) Through its Ratios - DWinneX
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results - TipRanks
Phio reports positive results in skin cancer trial - Investing.com
Phio reports positive results in skin cancer trial By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial - Newsfile
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile
Phio Pharmaceuticals (PHIO) to Release Earnings on Thursday - Defense World
Best Value Stocks to Buy for April 23rd - NewsBreak: Local News & Alerts
Analysts Advise You To Maintain Your Position In Phio Pharmaceuticals Corp (NASDAQ: PHIO) - Stocksregister
Best Momentum Stocks to Buy for April 23rd - TradingView
Ratio Revelations: Shuttle Pharmaceuticals Holdings Inc (SHPH)’s Financial Metrics in the Spotlight - DWinneX
Financial Snapshot: Analyzing Phio Pharmaceuticals Corp (PHIO)’s Key Ratio Metrics - DWinneX
Understanding the Risks of Investing in Phio Pharmaceuticals Corp (PHIO) - knoxdaily.com
Phio Pharmaceuticals Corp (PHIO) deserves closer scrutiny - uspostnews.com
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
As Cancer Rates Climb, Wall Street Turns Its Gaze Toward New Frontiers in Cancer Treatments - Baystreet.ca
Contrasting Phio Pharmaceuticals (NASDAQ:PHIO) and RespireRx Pharmaceuticals (OTCMKTS:RSPI) - Defense World
Equities Analysts Offer Predictions for PHIO FY2025 Earnings - Defense World
PHIO Stock Soars as Safety Panel Clears Skin Cancer Drug for Next Dose - MSN
3 Penny Stocks to Watch Now, 4/10/25 - TipRanks
Phio Pharmaceuticals Stock Soars On Clearance To Escalate Dose In Skin Cancer Treatment Trial: Retail’s Thrilled - MSN
Phio advances skin cancer treatment with successful trial By Investing.com - Investing.com South Africa
This Biotech Is Ripping Following Phase 1b Trial Announcement - The Globe and Mail
Crude Oil Down 4%; Neogen Shares Plunge After Q3 ResultsBloom Energy (NYSE:BE), Neogen (NASDAQ:NEOG) - Benzinga
Phio Pharmaceuticals Advances PH-762 Cancer Treatment in Phase 1 - GuruFocus
PHIO Advances PH-762 in Phase 1b Clinical Trial for Skin Cancers - GuruFocus
Is Phio’s Surge Sustainable? - timothysykes.com
Phio Pharmaceuticals Potential Skin Cancer Treatment Recommended for Dose Escalation - marketscreener.com
Phio advances skin cancer treatment with successful trial - Investing.com
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Study to Fourth Dose Escalation Cohort - Newsfile
Breakthrough in Skin Cancer Trial: PH-762 Shows 100% Tumor Clearance as Study Advances - Stock Titan
Phio stock hits 52-week low at $0.99 amid sharp annual decline - Investing.com
Phio Pharmaceuticals’ (PHIO) Buy Rating Reaffirmed at HC Wainwright - Defense World
Phio stock hits 52-week low at $0.99 amid sharp annual decline By Investing.com - Investing.com South Africa
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 - Investing.com Australia
H.C. Wainwright maintains Buy on Phio Pharma, target at $4.00 By Investing.com - Investing.com India
Phio Pharmaceuticals Announces Podium Presentations on INTASYL siRNA Lead Product Candidates PH-762 and PH-894 - Quantisnow
Phio Pharmaceuticals Corp Stock (PHIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Phio Pharmaceuticals Corp Stock (PHIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Bitterman Robert J | Chairman, Pres & CEO |
May 22 '25 |
Buy |
1.78 |
1,200 |
2,136 |
23,649 |
| Ferrara Robert L | Director |
May 20 '25 |
Buy |
1.82 |
2,500 |
4,550 |
13,166 |
| Bitterman Robert J | President & CEO |
Jun 07 '24 |
Buy |
0.74 |
1,000 |
740 |
20,990 |
| Bitterman Robert J | President & CEO |
Jun 06 '24 |
Buy |
0.75 |
1,000 |
750 |
19,990 |
2.38%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):